ACC 2017: SURTAVI Supports Intermediate-Risk Intervention For Medtronic's CoreValve

In an interview with Medtech Insight, the lead investigator of SURTAVI, an ongoing trial of Medtronic's CoreValve in intermediate risk patents, says transcatheter aortic valve is continuously improving and will probably soon be indicated for even low-risk patients, but that surgical valve replacement will have an important role to play for the foreseeable future.

Core Valve In Situ
Medtronic's CoreValve transcatheter aortic valve in situ • Source: SOURCE: Medtronic PLC

Two-year results of the Surgical Replacement and Transcatheter Aortic Valve Implantation (SURTAVI) trial show that transcatheter aortic valve replacement with Medtronic PLC's CoreValve or CoreValve Evolut R is noninferior to surgical valve replacement in patients with aortic stenosis at intermediate risk of complications during surgery.

"We made our two-year non-inferiority endpoint with very strong statistics," SURTAVI's lead investigator, surgeon Michael Reardon of Houston Methodist DeBakey Heart & Vascular Center, told Medtech Insight. Reardon presented the...

More from Cardiology

More from Device Area

FDLI: Clinical Labs Face Uncertainty After Texas Court’s LDT Ruling

 
• By 

A Texas court's decision against US FDA regulation of lab-developed tests (LDTs) has introduced new uncertainties for clinical labs. Industry stakeholders are now worried about potential future regulations while also managing existing compliance requirements. Recent conference discussions underscored the complexities of FDA oversight.

Data Finds Capillary Blood Is A Reliable Alternative To Venous Blood For Routine Testing

 

A study from Babson Diagnostics published in the peer-reviewed Journal of Applied Laboratory Medicine showed that capillary blood sample volume issues can overcome historical challenges, such as poor quality, through a technique called assay miniaturization.

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.